The thrombopoietin (TPO)‐activated c‐Mpl signaling pathway has been proven to promote megakaryocyte differentiation and platelet production and thus has significant value in the clinical treatment of ITP. This evidence concerns the gene MPL and autoimmune thrombocytopenic purpura.